| Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal. | |
| | |
MedLine Citation:
|
PMID: 19364454 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Until the end of the past century, a diagnosis of multiple sclerosis (MS) was often accompanied by a sense of apprehension, fueled primarily by the lack of available therapies and failed attempts with numerous agents. The modern era of MS therapeutics introduced in the past 20 years has helped to assuage the previous belief that little could be done to treat MS. The advent of disease-modifying treatments such as interferons and glatiramer acetate has had a notable impact on the course of MS. Numerous trials have demonstrated the clear benefit of initiating therapy in patients with a diagnosis of MS, but more importantly, they have shown that early initiation of treatment can delay progression to clinically definite MS in patients with clinically isolated syndrome who have concurrent changes on MRI. As newer agents become available, trials to assess their efficacy and tolerability are under way in an effort to expand the arsenal of available treatments. However, questions constantly resurface about the effect of treatments on disability, the safety of combination therapies, the role in neuroprotection, and other aspects. Moreover, recent attention regarding a radiologic and clinical dissociation, best illustrated by the anecdotally termed "radiologically isolated syndrome," highlights the frustrations facing clinicians when they try to predict disease course and the role of medications, if any.Despite the need for clear answers to these questions, the current practice is to initiate the available treatments early in patients with relapsing-remitting multiple sclerosis, in order to reduce the severity and frequency of clinical relapses. Treatment should also be initiated early in patients with clinically isolated syndrome because they are at high risk for developing clinically definite multiple sclerosis. |
| | |
Authors:
|
Krupa Pandey; Fred D Lublin |
Related Documents
:
|
8237704 - Multiple sclerosis presenting as parinaud syndrome. 8662124 - Mods/sirs: result of an overwhelming inflammatory response? 7334504 - Multiple pterygium syndrome. 21074464 - Childhood posterior reversible encephalopathy syndrome. 535894 - Omphalocele and partial trisomy 1q syndrome. 6222514 - Characterization of keratan sulfate isolated from liver affected by morquio syndrome. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current treatment options in neurology Volume: 11 ISSN: 1092-8480 ISO Abbreviation: Curr Treat Options Neurol Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-04-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9815940 Medline TA: Curr Treat Options Neurol Country: United States |
Other Details:
|
Languages: eng Pagination: 193-202 Citation Subset: - |
Affiliation:
|
Fred D. Lublin, MD Corinne Goldsmith Dickinson Center for Multiple Sclerosis, 5 East 98th Street, Box 1138, New York, NY 10029, USA. Fred.Lublin@mssm.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fatigue in Parkinson's disease patients.
Next Document: Pediatric multiple sclerosis.